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Ameloblastoma is a locally invasive benign neoplasm derived from odontogenic epithelium and 
presents with diverse phenotypes yet to be characterized molecularly. High recurrence rates of 50–80% 
with conservative treatment in some sub-types warrants radical surgical resections resulting in high 
morbidity. The objective of the study was to characterize the transcriptome of ameloblastoma and 
identify relevant genes and molecular pathways using normal odontogenic tissue (human “dentome”) 
for comparison. Laser capture microdissection was used to obtain neoplastic epithelial tissue from 
17 tumors which were examined using the Agilent 44 k whole genome microarray. Ameloblastoma 
separated into 2 distinct molecular clusters that were associated with pre-secretory ameloblast and 
odontoblast. Within the pre-secretory cluster, 9/10 of samples were of the follicular type while 6/7 of 
the samples in the odontoblast cluster were of the plexiform type (p < 0.05). Common pathways altered 
in both clusters included cell-cycle regulation, inflammatory and MAPkinase pathways, specifically 
known cancer-driving genes such as TP53 and members of the MAPkinase pathways. The pre-secretory 
ameloblast cluster exhibited higher activation of inflammatory pathways while the odontoblast cluster 
showed greater disturbances in transcription regulators. Our results are suggestive of underlying 
inter-tumor molecular heterogeneity of ameloblastoma sub-types and have implications for the use of 
tailored treatment.
Ameloblastoma is a slow-growing, locally invasive, benign epithelial odontogenic neoplasm. It is thought to be 
arise from SOX2-expressing dental lamina epithelium1, remnants of the tooth-forming enamel organ2. The tumor 
exhibits epithelial cells resembling pre-ameloblasts on a basement membrane in loosely arranged cells resembling 
stellate reticulum while the stroma consists of loose connective tissue. Although odontogenic tumors are rela-
tively rare, they constitute 3.8% of head and neck pathology, of which 40–50% are ameloblastoma3,4. Occasionally, 
ameloblastomas show malignant features or transform into malignancy5 and in rare cases metastasize6. Current 
treatment modalities range from conservative enucleation to radical excision and vary according to tumor sub-
type and location7,8. High recurrence rates (50–80%) have been observed in cases of conservative treatment9. 
Consequently, and despite recent advances in imaging-assisted surgical margin localization, post-operative his-
tological confirmation is still required. This forces surgeons to either act conservatively, risking the need for a 
second surgery, or act aggressively thus increasing morbidity10 and the need for extensive reconstructive surgery.
There are few genomics and transcriptomics studies of ameloblastoma, with most investigations focusing 
on candidate-genes. Moreover, different comparison tissues were used in the handful of microarray studies; 
including gingival tissue11,12, whole tooth buds13, dentigerous cysts14 and a universal human reference RNA15. 
Furthermore, whole tumor samples used in these studies included large portions of stromal tissue. In spite of the 
heterogeneity in comparison tissue, there have been advances in understanding tumorigenesis of ameloblastoma.
A recent study examining the whole transcriptome of ameloblastoma suggested the existence of distinct 
molecular subtypes12. It is envisaged that better understanding of the molecular basis of ameloblastoma can aid 
the identification of diagnostic and prognostic markers and may lead to the development of novel, personalized 
treatment protocols16. To address this knowledge gap, we embarked on this study aiming to characterize the 
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transcriptome of neoplastic ameloblastoma tissue and identify relevant molecular pathways and genes, using 
whole genome microarray.
Methods
Tumor collection and preparation. The study was conducted in accordance with approved human sub-
ject research guidelines and was approved by the local institutional review board and the ethics committee of the 
University of North Carolina-Chapel Hill. Between 2005 and 2008, 2 fresh frozen samples were obtained during 
surgical resection and 15 formalin-fixed paraffin-embedded (FFPE) samples were retrieved from the archives of 
the Department of Oral and Maxillofacial Pathology Laboratory, University of North Carolina (UNC) School of 
Dentistry. All samples were evaluated by a board-certified oral and maxillofacial pathologist and at least one other 
author and diagnoses were classified based on the 2005 WHO Histologic Classification of Odontogenic Tumors. 
Additional demographic data including gender, age, race, and tumor recurrence were recorded and examined for 
potential associations.
The fresh tumors including the bony resected margins were placed in RNAlater and Richard Allan Scientifics’ 
decalcifying solution (water, hydrochloric acid, EDTA, tetrasodium tartrate and potassium tartrate) at 4 °C for 
1–4 weeks. They were then frozen at − 80 °C before 7 μ m sections were obtained under RNAse-free conditions15, 
stained lightly with hematoxylin & eosin and sent for immediate laser capture microdissection (LCM). The FFPE 
blocks were decalcified before embedding in paraffin. The samples were sectioned, stained and sent for laser 
capture.
Laser capture microdissection. The AutoPixTM automated LCM system (Arcturus Engineering, Santa 
Clara, CA, USA) was used to isolate tumor cells (basal epithelial cells adjacent to the basement membrane). 
Images of the tissue sections including the captured regions were obtained before and after LCM.
RNA extraction and microarray. Laser-captured cells from each tumor were pooled and total RNA 
was isolated with the PicoPure RNA Isolation kit (Arcturus Bioscience, Santa Clara, CA, USA). The Agilent 
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA) was used to assess the yield and quality of total 
RNA. Amplification was completed on all samples using TargetAmpTM 2-Round Aminoallyl-aRNA Amplification 
Kit (Epicentre Biotechnologies, Madison, WI, USA).
RNA was then analyzed using the Agilent Whole Human Genome Microarray 4 × 44 K G4112F (Agilent 
Technologies, Palo Alto, CA) containing 44 thousand 60-mer oligonucleotides representing over 41 thousand 
human gene transcripts. For this step, 200 ng of RNA was converted into labeled cRNA with nucleotides coupled 
to fluorescent dye Cy3 using the Low RNA Input Linear Amplification Kit (Agilent Technologies, Palo Alto, CA) 
according to the manufacturer’s protocol. The Human Universal Reference RNA from Stratagene (Santa Clara, 
CA, USA) was coupled with Cy5. Cy3-labeled cRNA (1.65 ng) from each sample and the Cy5-labeled universal 
reference was hybridized to the Agilent whole genome array 41 k formatted chips. Data were extracted using 
Feature Extraction version 9.5 (Agilent Technologies, Palo Alto, CA). Background subtraction and Loess normal-
ization were performed using default setting of the Agilent extractor. The use of the universal RNA facilitated the 
use of the dentome as a comparison. It acts as a technical intra/inter normalizing control, decreasing variability by 
measuring signal output ratio of experimental to reference RNA rather than relying on absolute signal intensity 
two-color hybridization experiments17. The dentome consists of odontogenic tissue (microdissected samples of 
human odontoblasts, pre-secretory ameloblasts and secretory ameloblasts) expression data from previous work 
that employed the universal reference as a normalizing control18. The data set included 4 samples of each type 
of odontogenic tissue. It was collected from 12 anterior tooth buds (incisor and canine) from 4 different fetuses 
with each fetus contributing 3 tooth buds. Each type of odontogenic tissue was collected from a single tooth bud 
with each of the 3 buds providing a single type of odontogenic tissue or developmental stage. (Gene Expression 
Omnibus microarray database accession number GSE63289). The ameloblastoma expression data were submitted 
to the Gene Expression Omnibus microarray database (accession number GSE68531).
Microarray data analysis. A multiclass analysis was conducted between the 3 types of odontogenic tissue 
and the 60 genes differentially expressed at a false discovery rate (FDR) < 20% were designated as the odontogenic 
tissue-defining genes. The most appropriate comparison tissue was decided to be the normal tissue with the most 
similar profile to ameloblastoma, such that identified differences would be tumor specific. Cluster analysis was 
conducted using Cluster 3.0 between the 3 normal and tumor samples and visualized using Java TreeView-1.1.6r2.
Differential gene expression between tumors and comparison tissue were examined using Significance analy-
sis of microarrays (SAM) 4.0. Ingenuity pathway analysis was used to identify differentially expressed pathways. 
In addition, upstream analysis from the ingenuity pathway analysis software was conducted. Gene set enrichment 
analysis (GSEA)19 was conducted using GSEA v2.1.0 from the Broad institute (Cambridge, MA, USA) and the 
“all curated gene sets v4.0” available via the Molecular Signatures Database (MSigDB)20. Additionally, the amelo-
blastoma transcriptome was compared with the 13 cancer molecular subtypes from The Cancer Genome Atlas 
(TCGA) project21 to investigate possible correlation with other known cancer types.
Microarray gene expression validation using NanoString. A variety of approaches have been used 
to validate microarray data in the literature and NanoString was selected for the study. A random subset of 3 
ameloblastoma and 2 control odontogenic tissue samples was used to validate the microarray gene expression 
data. NanoString nCounter (Seattle, WA, USA) high throughput gene expression analysis22 was performed using 
the Human Cancer Reference codeset (http://www.nanostring.com/products/gene_expression_panels). Each 
reaction contained 50 ng of total sample RNA plus reporter and capture probes. Digital counts were extracted, 
normalized and analyzed using nSolver v2.5 software. Differential expression between ameloblastoma and 
pre-secretory ameloblast from nanoString was compared with that obtained from the microarray.
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Results
LCM facilitated the isolation of basal epithelial (neoplastic) cells from the tumor samples (Fig. 1) without con-
tamination from surrounding stroma cells. RNA was extracted from the LCM samples, with the 260/280 ratio 
for the 17 samples between 1.7–2.5 and a yield of between 88ng to 928ng (Supplemental Table 1). Quality control 
analysis conducted on the microarray chips indicated expected values for positive and negative controls, as well 
as uniformly high detected genes in both the red and green channels. Overall, no outliers were detected in either 
the normal tissue or tumor arrays indicating consistency in hybridization between samples.
NanoString validation. Due to the limited RNA quantity available, we did not conduct qPCR vali-
dation; instead, the NanoString platform was used to validate microarray gene expression data. Fold changes 
obtained with the nCounter system were correlated with those obtained from the microarray for the same sam-
ples (Supplementary Table 2). The 2 sets of expression data showed a good Pearson correlation (r = 0.61) in the 
scatter-plot (Supplementary Fig. 1).
Determination of comparison tissue. Unsupervised hierarchical cluster analysis was conducted for the 
tumor and normal tissue samples which showed the presence of 2 distinct clusters of ameloblastoma and a sepa-
rate cluster of normal odontogenic tissue (Supplementary Fig. 2). Supervised cluster analysis using the 60 odonto-
genic tissue defining genes showed that the 2 clusters of ameloblastoma associated most closely with pre-secretory 
ameloblast (PA) and odontoblast (OB) (Fig. 2A,B). As such, these 2 clusters were designated as the pre-secretory 
ameloblast-like ameloblastoma (pAM) and odontoblast-like ameloblastoma (oAM), respectively. Out of 10 sam-
ples in the pAM cluster, 9 were of the follicular type while 6/7 of the samples in the oAM cluster were of the plex-
iform type. (Fig. 2C). A Chi-Square analysis showed that the molecular clusters were significantly associated with 
a histological subtype (p < 0.05). A single comparison tissue could not be designated as the 2 clusters associated 
most closely with different odontogenic tissue; instead, a multiclass approach was employed.
Multiclass analysis. Multiclass analysis was conducted between the 2 tumor clusters and 2 associated nor-
mal tissues (pAM, oAM, PA, OB) and differentially expressed genes were carried forward in a cluster analy-
sis (Fig. 3A). To characterize the transcriptome of ameloblastoma and the 2 molecular sub-clusters, the gene 
Figure 1. The micrographs show the laser capture of the epithelial portion of an ameloblastoma sample. 
(A) – light micrograph of follicular ameloblastoma at 4X showing tumor epithelial follicles that are single-
cell thick with surrounding stroma. Arrows points to tumor follicles, (B) – light micrograph of follicular 
ameloblastoma at 20X showing the laser capture outline of epithelial cells, (C) – remnants of the stroma tissue 
after LCM and (D) – captured cells on capsure cap. Scale bar: 100 μ m.
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Canonical pathways different between the ameloblastoma common tumor cluster and normal cells
Biological process Ingenuity Canonical Pathways − log(p-value* ) Ratio z-score
Inflammatory (Immune) response/cytokine 
signaling
fMLP Signaling in Neutrophils 4.81 0.28 3.674
CXCR4 Signaling 2.68 0.21 1.961
TREM1 Signaling 2.34 0.25 −1.213
Thrombin Signaling 2.21 0.19 1.512
Acute Phase Response Signaling 2.20 0.20 2.117
IL-8 Signaling 2.12 0.19 2.785
Complement System 1.94 0.28 −1.89
Cell cycle regulation
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 4.23 0.35 − 1.069
Role of BRCA1 in DNA Damage Response 2.88 0.26 1.941
Cell Cycle: G1/S Checkpoint Regulation 1.63 0.22 −1.155
Cyclins and Cell Cycle Regulation 1.53 0.21 1.941
Cancer
Colorectal Cancer Metastasis Signaling 2.04 0.18 1
Pancreatic Adenocarcinoma Signaling 1.63 0.20 1.291
Glioblastoma Multiforme Signaling 1.40 0.18 2.132
Wnt/β -catenin Signaling 1.37 0.18 1.528
Actin Nucleation by ARP-WASP Complex 1.35 0.21 2.111
Map kinase related
Gα q Signaling 3.31 0.23 2.117
α -Adrenergic Signaling 2.77 0.25 1.069
Phospholipase C Signaling 1.83 0.18 1.461
Prolactin Signaling 1.74 0.22 3.051
Receptor tyrosine kinase (RTK)
Ephrin B Signaling 4.21 0.30 −1.155
Neuregulin Signaling 1.69 0.21 2.668
Nuclear receptor signaling Androgen Signaling 2.01 0.21 2.333
Cellular growth and proliferation Growth Hormone Signaling 1.32 0.20 1.941
Others
Cardiac β -adrenergic Signaling 1.87 0.20 2.138
Role of NFAT in Cardiac Hypertrophy 1.47 0.18 1.961
Canonical pathways different for the ameloblastoma presecretory cluster
Inflammatory (Immune) response/cytokine 
signaling 
Acute Phase Response Signaling 12.20 0.23 1.225
Production of Nitric Oxide and Reactive Oxygen Species 
in Macrophages 4.26 0.15 3.138
Extrinsic Prothrombin Activation Pathway 3.55 0.38 1.633
Leukocyte Extravasation Signaling 2.63 0.12 2.324
Role of NFAT in Regulation of the Immune Response 2.08 0.11 3
IL-8 Signaling 1.95 0.11 1.886
iCOS-iCOSL Signaling in T Helper Cells 1.91 0.13 2.333
Antioxidant Action of Vitamin C 1.80 0.13 −1.897
CD28 Signaling in T Helper Cells 1.60 0.12 2.333
TREM1 Signaling 1.55 0.13 1.667
Role of Pattern Recognition Receptors in Recognition of 
Bacteria and Viruses 1.44 0.11 1.897
eNOS Signaling 1.35 0.10 1.604
Cellular growth and proliferation
Growth Hormone Signaling 2.44 0.16 1.897
p70S6K Signaling 2.15 0.13 2.138
Mouse Embryonic Stem Cell Pluripotency 1.84 0.13 3.464
Oncostatin M Signaling 1.75 0.18 2.236
VEGF Signaling 1.63 0.12 2.121
Protein tyrosine kinase (PTK) Tec Kinase Signaling 1.73 0.11 1.387
Cancer
Colorectal Cancer Metastasis Signaling 1.71 0.10 1.706
Wnt/Ca+ pathway 1.68 0.15 1.89
Others
Melatonin Signaling 1.59 0.13 1.414
Endothelin-1 Signaling 1.45 0.10 2
Prolactin Signaling 1.41 0.12 2.121
Canonical pathways different for the ameloblastoma odontoblast cluster
Continued
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expression data were analyzed in 3 groups. The common tumor cluster describes differential gene expression 
common in both tumor clusters compared to normal tissue and comprises 2592 genes that were expressed at a 
higher and lower level in the 2 tumor clusters (pAM, oAM) compared to the 2 normal tissue clusters (OB, PA). 
The pAM cluster describes differential gene expression unique to that cluster and consists of 1287 genes expressed 
at higher and lower levels compared to the other 3 groups. The oAM cluster describes differential gene expression 
unique to oAM tumors and consists of 1516 genes expressed at a higher and lower levels compared to the other 3 
groups. The genes with fold changes at FDR < 1% were used for pathway analysis (Supplementary Table 3).
Pathway and gene set enrichment analysis. Ingenuity pathway analysis was used to examine the acti-
vated and inhibited canonical pathways for each tumor cluster (Table 1).
The common tumor cluster had 21 activated (z-score > 1) and 5 inhibited (z-score < − 1) pathways (Fig. 3B) 
at p-value < 0.05. Genes associated with notable biological processes that were differentially expressed in all the 
ameloblastoma tumors included prevention of damage to cell cycle regulation, cancer pathways, inflammatory 
pathways and Map kinase related pathways.
In addition, GSEA conducted between the common tumor cluster and normal tissues showed that 1860 out of 
the 2381 genes sets in the “all curated gene sets v4.0” were up-regulated in the common tumor cluster. Nineteen 
upregulated gene sets were significantly enriched at the nominal p-value < 0.05. (Supplementary Table 4).
The pre-secretory ameloblast tumor cluster had 22 activated and 1 inhibited pathway below the critical p-value 
threshold (Fig. 3C). Pathway analysis showed activation in the known cancer pathways, several inflammatory 
pathways and EGFR pathways.
The odontoblast tumor cluster had 1 activated and 8 inhibited pathways (Fig. 3D). Several inflammatory path-
ways were found to be inhibited in this cluster.
Upstream analysis. Upstream regulators that were predicted to be activated or inhibited are listed in 
Table 2. Most of the predicted upstream regulators in the common tumor cluster were transcription regulators, 
kinases and cytokines. Specifically, several Map kinase members and inflammatory cytokines were predicted to 
be activated.
Correlation with The Cancer Genome Atlas. The 2 molecular subtypes of ameloblastoma were com-
pared with the transcriptome of the cancer subtypes in TCGA (Supplementary Fig. 3). The analysis did not 
show any significant correlation of ameloblastoma with any of the 13 subtypes of cancers that are well studied 
and has established treatment protocols. As ameloblastoma does not seem to correlate molecularly with the can-
cer subtypes, more investigation into ameloblastoma tumorigenesis is needed for the development of effective 
treatment.
Discussion
The major finding of this study was the molecular heterogeneity of ameloblastoma that was strongly associated 
with its histological subtypes. Gene expression profiles of follicular and plexiform subtypes were more closely 
related to gene expression profiles of different normal odontogenic tissues and the follicular subtype showed acti-
vation of different molecular pathways compared with the plexiform subtype. This new knowledge can serve as a 
rich hypothesis-generating resource for the study of molecular and phenotypic characteristics of ameloblastoma.
One of the strengths of this study was the use of LCM for the examination of odontogenic tumors. The ability 
of LCM to isolate one cell-thick discrete tissue populations23 facilitates the targeting and pooling of neoplas-
tic epithelial portions of ameloblastoma. Similar to the present study, Heikinheimo and colleagues found that 
ameloblastoma gene expression is heterogeneous, and identified 2 distinct tumor clusters with gene expression 
profile that were most similar to gene expression in the cap/bell stage of tooth development12. Using supervised 
cluster analysis we found that more than half of ameloblastoma samples were most similar in gene expression to 
pre-secretory ameloblast, similar to those observed in the early cap/bell stage as described by Heikinheimo. The 
remaining ameloblastoma samples were associated with the mesenchymal-derived odontoblast rather than the 
epithelial-derived ameloblast; this appears to be driven by differences in inflammatory pathways and was asso-
ciated with a different histological appearance. However, the early pre-secretory ameloblast in this sample could 
Canonical pathways different between the ameloblastoma common tumor cluster and normal cells
Biological process Ingenuity Canonical Pathways − log(p-value* ) Ratio z-score
Inflammatory (Immune) response/cytokine 
signaling 
Leukocyte Extravasation Signaling 3.99 0.16 − 2.524
Acute Phase Response Signaling 3.51 0.16 1.897
Extrinsic Prothrombin Activation Pathway 2.30 0.31 − 1.342
TREM1 Signaling 1.89 0.16 − 1.508
Complement System 1.80 0.19 − 1
Production of Nitric Oxide and Reactive Oxygen Species 
in Macrophages 1.33 0.11 − 2.236
Nuclear receptor signaling LXR/RXR Activation 5.57 0.21 − 1.225
Cancer Colorectal Cancer Metastasis Signaling 2.67 0.13 − 3.157
Cellular growth and proliferation Mouse Embryonic Stem Cell Pluripotency 2.01 0.15 − 3.207
Table 1.  Canonical pathways differentially expressed in ameloblastoma clusters. * p-value  <  0.05.
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be more appropriately described as preameloblast from the early cap stage of tooth development. Preameloblasts 
share a number of genes with odontoblasts due to significant cross-talk during differentiation; it is therefore 
unsurprising that a cluster of ameloblastoma was associated with odontoblast.
The examination of pathways common to both tumors shows that inflammation appears to play an important 
role in ameloblastoma tumorigenesis and proliferation. This finding is similar to an earlier microarray study 
showing increased expression levels of inflammatory mediators13. Canonical pathway analysis showed that sev-
eral immune/inflammatory pathways are activated in addition to several predicted activated upstream cytokines. 
The association between dysregulated inflammation and cancer progression has been studied extensively24. The 
greater number of pathways activated in the pre-secretory cluster suggests that this process may be more impor-
tant in the follicular subtype.
The Wnt signaling pathway is important in the development of ameloblastoma as discussed in the microarray 
study by DeVilliers15. Some investigators found the activation of beta-catenin downstream of Wnt signaling25 
while others found that expression of various Wnt pathways differ among ameloblastoma with the canonical Wnt 
pathway being the main transduction pathway26. In this study, the canonical Wnt/β -catenin Signaling pathway 
was found to be activated in the common tumor cluster, highlighting its importance in tumorigenesis.
Additionally, both tumor clusters revealed that damage to cell cycle regulation pathways play important roles. 
Alteration in cell cycle regulation has been found by other investigators examining ameloblastoma gene expres-
sion11,14. A key regulator in the cell cycle damage prevention pathways is TP53 which is also predicted to be 
inhibited in our upstream analysis. TP53 is a major tumor suppression gene27 and the loss of a tumor suppressor 
gene activity in ameloblastoma may be important in the tumorigenesis process. Although the dental epithelium 
defining SOX2 was not found to be differentially expressed, SOX11 of the same family of transcription factors 
related to oncogenic transformation28 was found to be inhibited in the tumor samples.
Several canonical pathways involving the MAPK pathways and upstream members were found to be activated 
in the common tumor cluster. The MAPK pathways have long been considered tumor driver pathways in the 
pathogenesis of various cancers and are thought to be important in ameloblastoma tumorigenesis29,30. Although 
the expression levels of usual targets such as BRAF and EGFR were not directly increased, activation of the path-
way suggests alterations in the activity of the members. Recently, Kurppa and colleagues found BRAF gene muta-
tions, specifically V600E mutation, in 63% of ameloblastomas31. BRAF is in the RAS pathway and MAPK cascade. 
This mutation leads to a 500 fold increase in activity of BRAF and increases signals through MEK to activate 
ERK32. ERK is the activator of numerous downstream transcription factors which induces biochemical functions 
such as cell differentiation, proliferation, growth, and apoptosis. The V600E mutation in BRAF is a promising 
Figure 2. Cluster analysis used to determine reference tissue. (A) – Heat map of the 3 different odontogenic 
tissues (OB – Odontoblast, PA – Pre-secretory ameloblast, SA – Secretory ameloblast) and the 2 distinct 
clusters of Ameloblastoma (AM) clustered using the 60 odontogenic epithelium-defining genes. (B) – Array 
tree showing grouping of the 2 clusters with odontoblast and pre-secretory ameloblast. (C) – Participant 
demographic  and tumor phenotype.
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oncogene target for the anti-neoplastic drug dabrafenib; which was used in conjunction with a MEK inhibitor in 
a patient with stage 4 ameloblastoma with good results33. The use of chemotherapeutic agents to reduce tumor 
size can be very helpful in cases of ameloblastoma requiring extensive surgical margins and major post-surgical 
reconstruction34.
In GSEA, the gene sets with the highest activation scores, were cancer related including “SMID_
BREAST_CANCER_LUMINAL_A_DN”. Cancer related pathways were also found to be differentially 
expressed in our pathway analysis. Moreover, breast cancer specific “Role of BRCA1 in DNA Damage 
Response” pathway was found to be differentially expressed, with the 2 different analyses highlighting sim-
ilar molecular pathways.
One of the short-comings of this study is that most of the samples were FFPE. Formalin fixing can cause 
the degradation of RNA35 and affect the accuracy of microarrays. However, recent studies supported the use 
of such samples for gene expression analysis36 and NanoString has been shown to produce consistent results 
independent of the sample type (fresh frozen versus FFPE)37. Genes in our microarray data that had the greatest 
fold changes showed good correlation with the nanoString expression. In addition, there were no outliers in the 
cluster analysis among the ameloblastoma cluster analysis indicating consistent results between fresh frozen and 
FFPE samples.
Strengths of the study included the use of LCM and universal RNA as a means of normalizing between arrays. 
Ameloblastoma presents with neoplastic epithelial tissue surrounded by stromal tissue making isolation very dif-
ficult. As a result, most investigations of ameloblastoma used samples that contain diverse cell populations such 
as the surrounding stroma which can obscure driver pathways from the actual neoplastic epithelial cells. The use 
of the universal RNA facilitated the use of the dentome as a comparison and also allows the use of the microarray 
data by other investigators using universal RNA for normalization.
In conclusion, our study isolated ameloblastoma epithelial and normal odontogenic cells using LCM to iden-
tify gene expression profiles and molecular pathways that are potentially important in the tumorigenesis of amelo-
blastoma. Ameloblastoma showed 2 distinct molecular profiles that were associated with different histological 
Figure 3. Multiclass and pathway analysis of the different tumor clusters. (A) – Heat map of the genes 
with a FDR < 1% that are differentially expressed in the 4 clusters (OB – odontoblast, PA – pre-Secretory 
Ameloblast, oAM – odontoblast-like ameloblastoma, pAM – pre-secretory Ameloblast-like ameloblastoma) 
from a SAM multiclass analysis. The cluster tree on the right shows the 2 distinct clusters of ameloblastoma. 
Groups of genes with similar expression (identified by colored bars at the bottom of the heat map) were used 
for pathway analysis for the different clusters of ameloblastoma which were shown in (B–D). (B) – Canonical 
pathways that are differentially expressed for the Common tumor cluster in IPA. (C) – Canonical pathways that 
are differentially expressed for the Pre-secretory ameloblast cluster in IPA. (D) – Canonical pathways that are 
differentially expressed for the odontoblast cluster in IPA.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:30867 | DOI: 10.1038/srep30867
Activated and inhibited molecules in Common Tumor Cluster
Molecule Type
Upstream 
Regulator
Predicted 
Activation State
Activation 
z-score
p-value of 
overlap
transcription regulator
SOX11 Inhibited − 2.16 0.47
NUPR1 Inhibited − 2.46 0.00
NEUROG1 Inhibited − 2.18 0.00
KDM5B Inhibited − 3.66 0.00
TP53 Inhibited − 2.37 0.00
HIF1A Activated 2.90 0.00
JUN Activated 2.55 0.00
FOXM1 Activated 2.99 0.00
EZH2 Activated 2.06 0.10
YAP1 Activated 2.21 0.01
MYB Activated 2.39 0.00
kinase
TRIB3 Inhibited − 2.00 0.10
CDKN1A Inhibited − 2.60 0.00
AKT1 Activated 2.65 0.01
EGFR Activated 2.20 0.04
MAPK9 Activated 2.31 0.02
PIM1 Activated 2.42 0.05
MAP3K14 Activated 2.21 0.13
EIF2AK2 Activated 2.43 0.01
ERBB2 Activated 2.46 0.00
cytokine
CSF2 Activated 2.43 0.01
TNF Activated 2.27 0.00
IL1A Activated 2.12 0.00
IL6 Activated 3.33 0.01
OSM Activated 2.41 0.00
enzyme
STUB1 Inhibited − 2.24 0.03
HRAS Activated 2.16 0.00
ligand-dependent nuclear receptor
PGR Activated 3.22 0.00
ESRRA Activated 2.20 0.07
transporter
SLC29A1 Activated 2.00 0.14
S100A6 Activated 2.12 0.01
complex
IgG Inhibited − 2.04 0.00
NFkB (complex) Activated 2.35 0.00
Cg Activated 2.69 0.00
group
STAT5a/b Activated 2.00 0.55
Mek Activated 2.36 0.05
Growth hormone Activated 2.55 0.06
transmembrane receptor TREM1 Activated 2.82 0.00
growth factor NRG1 Activated 2.17 0.06
other
RBM5 Inhibited − 2.34 0.07
UXT Inhibited − 2.44 0.01
AHI1 Activated 2.00 0.24
RABL6 Activated 3.30 0.00
HSPB2 Activated 2.22 0.00
Activated and inhibited molecules in Presecretory Cluster
enzyme MGEA5 Inhibited −2.04 0.00
ligand-dependent nuclear receptor PPARG Activated 2.01 0.00
transcription regulator NUPR1 Activated 2.11 0.00
growth factor WISP2 Activated 2.24 0.06
Activated and inhibited molecules in Odontoblast Cluster
transcription regulator
SOX11 Inhibited −2.98 0.05
MDM2 Inhibited − 2.24 0.04
CEBPA Inhibited − 2.14 0.00
NUPR1 Inhibited − 2.47 0.36
TP53 Inhibited − 2.19 0.01
Continued
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subtypes suggesting they could be receptive to different chemotherapeutic protocols. These results provide a 
wealth of information that can be used in future experimental and mechanistic studies, involving animal models 
and new pharmacogenomic approaches.
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